The company said, “With the current order flow and potential unit demand expected from soon-to-close pipeline accounts for IHEEZO, TRIESENCE, and other operational improvements across the rest of our business, we remain confident that we will achieve – and hopefully exceed – our 2025 revenue target of over $280 million. We also remain committed to pursuing strategic acquisitions that add high-quality ophthalmic pharmaceutical assets to our best-in-class U.S. commercial platform.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow expands Vevye Access for All program
- Harrow price target lowered to $65 from $69 at B. Riley
- Harrow Health’s Strong Financial Performance and Growth Prospects Justify Buy Rating and $57 Price Target
- Harrow Health Reports Strong 2024 Financial Performance
- Closing Bell Movers: Lululemon falls 10% on soft guidance